2. Signaling Pathways
  3. PI3K/Akt/mTOR
  4. PI3K
  5. PI3K Ligand

PI3K Ligand

PI3K Isoform Comparison

PI3K Ligands (8):

Cat. No. Product Name Effect Purity
  • HY-203618
    PI3K/mTOR ligand-1
    		Ligand
    PI3K/mTOR ligand-1 is a ligand for the target protein of PROTAC (PI3K/mTOR). PI3K/mTOR ligand-1 can be used to synthesize GP262 (HY-180261).
  • HY-159852
    BBO-10203
    		Ligand 99.12%
    BBO-10203 is a potent inhibitor of PI3Kα and KRASG12C, selectively and covalently binding to Cys242 in the RAS-Binding Domain of PI3Kα, and inhibiting both the GTP-bound and GDP-bound states of KRASG12C with an IC50 of 0.031 nM and an EC50 of 0.02 nM. BBO-10203 disrupts the interaction between RAS isoforms and PI3Kα, leading to the inhibition of RAS-mediated PI3Kα activation, and reduces pERK expression, cell growth, and induces G1 arrest and apoptosis. BBO-10203 can be used for the research of breast cancer, colorectal cancer, and non-small cell lung cancer.
  • HY-N4246
    Bacopaside I
    		Ligand 99.20%
    Bacopaside I is an orally active aquaporin AQP1 inhibitor and PKC modulator with neuroprotective and anticancer activities. Bacopaside I specifically blocks the water channel and cGMP-gated ion channel activities of AQP1 without affecting AQP4, thereby inhibiting the migration of colon cancer cells expressing AQP1. Bacopaside I activates the Akt pathway by interacting with PI3K, specifically inhibits MAO-A, effectively alleviates neuron necrosis and apoptosis induced by oxygen-glucose deprivation, reduces oxidative stress, and regulates the surface expression of neuroreceptors. When combined with Bacopaside II (HY-N6016), Bacopaside I significantly reduces the viability, proliferation and invasion ability of breast cancer cells, and binds to the pregnane X receptor (PXR). Bacopaside I is applicable to the research of colon cancer, breast cancer, vascular dementia, cerebral ischemia and other related diseases.
  • HY-174798
    PI3Kα Ligand-1
    		Ligand 98.0%
    PI3Kα Ligand-1 is the ligand for PI3Kα that can be used for synthesis of PROTACs, such as PI3Kα degrader-1 (HY-174461).
  • HY-P10981
    ErbB2 peptide
    		Ligand
    ErbB2 peptide is a peptide ligand of E3 ubiquitin ligase targeting PI3K for peptide PROTACs.
  • HY-N4246R
    Bacopaside I (Standard)
    		Ligand
    Bacopaside I (Standard) is the analytical standard of Bacopaside I. This product is intended for research and analytical applications. Bacopaside I is an orally active aquaporin AQP1 inhibitor and PKC modulator with neuroprotective and anticancer activities. Bacopaside I specifically blocks the water channel and cGMP-gated ion channel activities of AQP1 without affecting AQP4, thereby inhibiting the migration of colon cancer cells expressing AQP1. Bacopaside I activates the Akt pathway by interacting with PI3K, specifically inhibits MAO-A, effectively alleviates neuron necrosis and apoptosis induced by oxygen-glucose deprivation, reduces oxidative stress, and regulates the surface expression of neuroreceptors. When combined with Bacopaside II (HY-N6016), Bacopaside I significantly reduces the viability, proliferation and invasion ability of breast cancer cells, and binds to the pregnane X receptor (PXR). Bacopaside I is applicable to the research of colon cancer, breast cancer, vascular dementia, cerebral ischemia and other related diseases.
  • HY-N0859A
    Schisanhenol B
    		Ligand
    Schisanhenol B is one of the active ingredients of schisandra chinensis. Schisanhenol B is a tyrosinase inhibitor. Schisanhenol B has good binding activity with PIK3CG and can be used in the study of heart failure.
  • HY-182086
    Copanlisib-NH
    		Ligand
    Copanlisib-NH is a PI3Kα/δ ligand. Copanlisib-NH can be used as a ligand for target protein for PROTAC to develop and design degraders of PROTAC PI3Kα/δ, such as PROTAC PI3Kα/δ degrader-1 (HY-182083). Copanlisib-NH can be used in breast cancer research.